Biotechnology News

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a...

MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

ST. LOUIS, March 31, 2026 (GLOBE NEWSWIRE) -- MediBeacon Inc., a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, today...

IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2...

ROCKAWAY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Seth Abrams...

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases...

WHITE PLAINS, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Iantrek, Inc., a pioneer and leader in bio-interventional ophthalmic surgery (BIOS), today announced the introduction and US controlled release...

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved...

Company announcement no. 8 - 2631 March 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

Lehi, UT, March 31, 2026 (GLOBE NEWSWIRE) -- Lehi, Utah, March 31, 2026 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to...